Program Director
Mikko Niemi
Clinical Pharmacology and Pharmacogenetics
Biomedicum 2C 307
Haartmaninkatu 8
00014 University of Helsinki
tel. +358 50 428 0998
mikko.niemi@helsinki.fi
Recent and ongoing advances in the methods in genomic and pharmacokinetic analyses, as well as the facilitating changes in the legislative environment open up novel possibilities to investigate the individualization of drug therapies. The Individualized Drug Therapy Research Program brings together groups involved in basic, translational and clinical drug research. The synergistic interdisciplinary combination of experts in in vitro and animal models, pharmacokinetics, pharmacogenetics, systems pharmacology and modeling, as well as clinical research in major therapeutic areas forms a cutting-edge center of individualized drug therapy.
Principal Investigators
- Janne Backman - Clinical Pharmacology and Pharmacogenetics
- Erkki Isometsä
- Michael Jeltsch - Lymphangiogenesis Research and Antibody Development
- Sinem Karaman
- Katri Koli - Growth Factor Group
- Sirpa Loukovaara - Translational Diabetic Retinopathy and Fibrovascular Complications
- Marjukka Myllärniemi - Lung Factor
- Klaus Olkkola
- Pekka Rauhala
- Kim Vettenranta
- Tuomas Lilius ( Junior PI )
Associated Clinical Researchers
- Martti Färkkilä
- Jukka Kanerva
- Heli Malm
- Kimmo Porkka
Seminars
Individrug monthly seminar series
Key Publications from INDIVIDRUG
-
Lilius TO, Blomqvist K, Hauglund NL, Liu G, Stæger FF, Bærentzen S, Du T, Ahlström F, Backman JT, Kalso EA, Rauhala PV, Nedergaard M. Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs. Journal of Control Release, 2019, 28(304):29-38.
-
Jha SK, Rauniyar K, Chronowska E, Mattonet K, Maina EW, Koistinen H, Stenman U-H, Alitalo K, Jeltsch M. KLK3/PSA and Cathepsin D activate VEGF-C and VEGF-D. eLife, 2019, Vol 8: e44478.
-
Tornio A, Filppula AM, Niemi M & Backman JT. Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. Clinical Pharmacology and Therapeutics, 2019, 105(6):1345-1361.
-
Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M & Backman JT. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clinical Pharmacology and Therapeutics, 2019, 105(1):219-228.
-
Hirvensalo P, Tornio A, Neuvonen M, Kiander W, Kidron H, Paile-Hyvärinen M, Tapaninen T, Backman JT, Niemi M. Enantiospecific pharmacogenomics of fluvastatin. Clinical Pharmacology and Therapeutics, 2019, 106(3):668-680.
-
Pett H, Bradley J, Okebe J, Dicko A, Tiono AB, Goncalves BP, Stone W, Chen I, Lanke K, Neuvonen M, Mustaniemi A-L, Eziefula AC, Gosling R, D'Alessandro U, Drakeley C, Niemi M, Bousema T. CYP2D6 Polymorphisms and the Safety and Gametocytocidal Activity of Single-Dose Primaquine for Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2019, 63(10).
-
Holma KM, Holma I, Ketokivi M, Oquendo MA, Isometsä E. The Relationship Between Smoking and Suicidal Behavior in Psychiatric Patients with Major Depressive Disorder. Archives of Suicide Research, 2019, 23(4):590-604.
- Mian P, van Esdonk MJ, Olkkola KT, de Winter BCM, Liukas A., Spriet i, Tibboel D, Petrovic M, Koch BCP, Allegaert K. Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. British Journal of Clinical Pharmacology, 2019, 85(1):126-135.
- Ifversen M, Turkiewicz D, Marquart HV, Winiarski J, Buechner J, Mellgren, K, Arvidson J, Rascon J, Körgvee L-T, Madsen HO, Abrahamsson J, Lund B, Jonsson OG, Heilmann C, Heyman M, Schmiegelow K, Vettenranta, K. Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience. British Journal of Haematology, 2019, 184(6): 982-993.
-
Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, Rouvinen E, Lemström K, Räsänen J, Ritvos O, Koli K, Myllärniemi M. Elevated circulating activin A levels in malignant pleural mesothelioma patients are related to cancer cachexia and reduced response to platinum-based chemotherapy. Clinical Lung Cancer, 2019, S1525-7304:30287-6.